According to the latest report by IMARC Group, titled "Leber Congenital Amaurosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033," the global Leber congenital amaurosis market size is anticipated to grow at a CAGR of 4.50% during 2023-2033. Leber congenital amaurosis (LCA) refers to a rare genetic disorder that affects the part of the eye that is responsible for detecting light and transmitting visual information to the brain. It is caused by mutations in one of several genes involved in the development and function of the retina. These mutations disrupt the normal processes of the retina, leading to progressive degeneration and loss of function. Its symptoms include poor visual tracking, involuntary eye movements, light sensitivity, and poor pupil responses. In some cases, children with LCA encounter a reduction in their visual acuity, struggle with visual tracking and eye coordination, and find it challenging to discern fine details. A comprehensive eye examination is typically conducted to diagnose LCA, which includes visual acuity and visual field testing as well as an examination of the retina and optic nerve. Additional several tests, such as electroretinography (ERG), optical coherence tomography (OCT), and genetic testing, are also performed to confirm the diagnosis and determine the underlying genetic cause.
Global Leber Congenital Amaurosis Market Trends:
The rising incidences of inherited eye diseases are driving the global market. Coupled with this, the growing prevalence of chronic diseases, including diabetes and gastrointestinal disorders, is also contributing to the market across the globe. Moreover, the growing demand for treatments that can slow vision loss and improve quality of life is significantly supporting the market. In line with this, continuous advancements in gene therapy research, improvements in genetic testing and diagnosis, and the development of new visual aids and rehabilitation techniques are further propelling the demand. Furthermore, the widespread adoption of non-invasive imaging tests, such as optical coherence tomography is aiding in the diagnosis of retinal diseases, which is contributing to the market worldwide. Along with this, several key players are heavily investing in understanding the genetic causes of LCA to develop new therapies, thus creating a positive market outlook. Apart from this, the use of low-vision devices and the availability of educational and advocacy resources for LCA patients and their families is strengthening the market. Moreover, the growing popularity of occupational therapy and rehabilitation services among individuals with LCA for improving their daily living activities is impacting the market favorably. Other factors, such as extensive research and development activities by leading players, ongoing innovations in the treatment of inherited retinal diseases, and continuous improvements in healthcare infrastructure, are also propelling the market.
- On the basis of the countries covered, the market has been categorized into the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800